Menu
Back to Journals » Degenerative Neurological and Neuromuscular Disease
Degenerative Neurological and Neuromuscular Disease
- View all (96)
- Volume 10, 2020 (3)
- Volume 9, 2019 (11)
- Volume 8, 2018 (8)
- Volume 7, 2017 (10)
- Volume 6, 2016 (11)
- Volume 5, 2015 (12)
- Volume 4, 2014 (13)
- Volume 3, 2013 (8)
- Volume 2, 2012 (14)
- Volume 1, 2011 (6)
Journal Articles:
- 96 records -
Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy
Goldschmidt CH, Hua LH
Degenerative Neurological and Neuromuscular Disease 2020, 10:29-38
Published Date: 26 June 2020
Dysphagia In Multiple Sclerosis Patients: Diagnostic And Evaluation Strategies
Ansari NN, Tarameshlu M, Ghelichi L
Degenerative Neurological and Neuromuscular Disease 2020, 10:15-28
Published Date: 26 March 2020
Prostaglandins as the Agents That Modulate the Course of Brain Disorders
Famitafreshi H, Karimian M
Degenerative Neurological and Neuromuscular Disease 2020, 10:1-13
Published Date: 16 January 2020
Alzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen J, Langerman H
Degenerative Neurological and Neuromuscular Disease 2019, 9:123-130
Published Date: 24 December 2019
Progressive Multifocal Leukoencephalopathy: Current Insights
Kartau M, Sipilä JOT, Auvinen E, Palomäki M, Verkkoniemi-Ahola A
Degenerative Neurological and Neuromuscular Disease 2019, 9:109-121
Published Date: 2 December 2019
Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
Ghanekar SD, Miller WW, Meyer CJ, Fenelon KJ, Lacdao A, Zesiewicz TA
Degenerative Neurological and Neuromuscular Disease 2019, 9:103-107
Published Date: 15 October 2019
Clinical and research applications of neuromuscular ultrasound in amyotrophic lateral sclerosis
Barnes SL, Simon NG
Degenerative Neurological and Neuromuscular Disease 2019, 9:89-102
Published Date: 16 July 2019
Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease
Lilli NL, Révy D, Robelet S, Lejeune B
Degenerative Neurological and Neuromuscular Disease 2019, 9:79-88
Published Date: 8 July 2019
Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials
Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T
Degenerative Neurological and Neuromuscular Disease 2019, 9:55-78
Published Date: 1 July 2019
Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
Goischke HK
Degenerative Neurological and Neuromuscular Disease 2019, 9:39-53
Published Date: 13 June 2019
Lambert-Eaton Myasthenic syndrome: early diagnosis is key
Ivanovski T, Miralles F
Degenerative Neurological and Neuromuscular Disease 2019, 9:27-37
Published Date: 13 May 2019
Sialorrhea in patients with ALS: current treatment options
Garuti G, Rao F, Ribuffo V, Sansone VA
Degenerative Neurological and Neuromuscular Disease 2019, 9:19-26
Published Date: 20 March 2019
The effects of huntingtin-lowering: what do we know so far?
Kaemmerer WF, Grondin RC
Degenerative Neurological and Neuromuscular Disease 2019, 9:3-17
Published Date: 8 March 2019
Editorial announcing PubMed indexing of Degenerative Neurological and Neuromuscular Disease
Müller T
Degenerative Neurological and Neuromuscular Disease 2019, 9:1-2
Published Date: 27 December 2018
Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies
Preziosi G, Gordon-Dixon A, Emmanuel A
Degenerative Neurological and Neuromuscular Disease 2018, 8:79-90
Published Date: 6 December 2018
Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy – Phase I–II
Dai A, Baspinar O, Yeşilyurt A, Sun E, İnci Aydemir C, Öztel ON, Capkan DU, Pinarli F, Agar A, Karaöz E
Degenerative Neurological and Neuromuscular Disease 2018, 8:63-77
Published Date: 26 October 2018
Continuous noninvasive ventilation for respiratory failure in patients with amyotrophic lateral sclerosis: current perspectives
Fiorentino G, Annunziata A, Gaeta AM, Lanza M, Esquinas A
Degenerative Neurological and Neuromuscular Disease 2018, 8:55-61
Published Date: 4 September 2018
Physical therapy for individuals with amyotrophic lateral sclerosis: current insights
Dal Bello-Haas V
Degenerative Neurological and Neuromuscular Disease 2018, 8:45-54
Published Date: 16 July 2018
Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis
Boyko AN, Boyko OV
Degenerative Neurological and Neuromuscular Disease 2018, 8:35-44
Published Date: 3 May 2018
Spotlight on postural control in patients with multiple sclerosis
Prosperini L, Castelli L
Degenerative Neurological and Neuromuscular Disease 2018, 8:25-34
Published Date: 3 April 2018
Employment of patients with multiple sclerosis: the influence of psychosocial-structural coping and context
Vijayasingham L, Mairami FF
Degenerative Neurological and Neuromuscular Disease 2018, 8:15-24
Published Date: 26 March 2018
Biomarkers of Duchenne muscular dystrophy: current findings
Al-Khalili Szigyarto C, Spitali P
Degenerative Neurological and Neuromuscular Disease 2018, 8:1-13
Published Date: 25 January 2018
Erythrocyte membrane in the evaluation of neurodegenerative disorders
Sadanand A, Janardhanan A, Sankaradoss A, Vanisree AJ, Arulnambi T, Bhanu K
Degenerative Neurological and Neuromuscular Disease 2017, 7:127-134
Published Date: 17 October 2017
Current concepts in multiple sclerosis therapy
Sedal L, Winkel A, Laing J, Law LY, McDonald E
Degenerative Neurological and Neuromuscular Disease 2017, 7:109-125
Published Date: 28 September 2017
Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions
Ngo ST, Mi JD, Henderson RD, McCombe PA, Steyn FJ
Degenerative Neurological and Neuromuscular Disease 2017, 7:95-108
Published Date: 25 July 2017
Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study
Bisht B, Darling WG, White EC, White KA, Shivapour ET, Zimmerman MB, Wahls TL
Degenerative Neurological and Neuromuscular Disease 2017, 7:79-93
Published Date: 26 June 2017
Characteristics of tongue and pharyngeal pressure in patients with neuromuscular diseases
Umemoto G, Furuya H, Tsuboi Y, Fujioka S, Arahata H, Sugahara M, Sakai M
Degenerative Neurological and Neuromuscular Disease 2017, 7:71-78
Published Date: 30 May 2017
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
Hinchcliffe M, Smith A
Degenerative Neurological and Neuromuscular Disease 2017, 7:61-70
Published Date: 29 May 2017
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
Furber KL, Van Agten M, Evans C, Haddadi A, Doucette JR, Nazarali AJ
Degenerative Neurological and Neuromuscular Disease 2017, 7:47-60
Published Date: 24 March 2017
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
Feng JJ, Ontaneda D
Degenerative Neurological and Neuromuscular Disease 2017, 7:31-45
Published Date: 1 February 2017
Biomarkers of multiple sclerosis: current findings
Harris VK, Tuddenham JF, Sadiq SA
Degenerative Neurological and Neuromuscular Disease 2017, 7:19-29
Published Date: 12 January 2017
Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study
Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG
Degenerative Neurological and Neuromuscular Disease 2017, 7:1-18
Published Date: 4 January 2017
Respiratory management of patients with neuromuscular disease: current perspectives
Pfeffer G, Povitz M
Degenerative Neurological and Neuromuscular Disease 2016, 6:111-118
Published Date: 18 November 2016
Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
Milo R, Stüve O
Degenerative Neurological and Neuromuscular Disease 2016, 6:95-109
Published Date: 17 November 2016
Challenges faced in managing dementia in Alzheimer’s disease in patients with Down syndrome
Prasher VP, Mahmood H, Mitra M
Degenerative Neurological and Neuromuscular Disease 2016, 6:85-94
Published Date: 20 September 2016
Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights
Ostergaard JR
Degenerative Neurological and Neuromuscular Disease 2016, 6:73-83
Published Date: 1 August 2016
Palliative care for patients with motor neurone disease: current challenges
Oliver DJ
Degenerative Neurological and Neuromuscular Disease 2016, 6:65-72
Published Date: 26 May 2016
The genetics of amyotrophic lateral sclerosis: current insights
Alsultan AA, Waller R, Heath PR, Kirby J
Degenerative Neurological and Neuromuscular Disease 2016, 6:49-64
Published Date: 13 May 2016
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
Namgoong JH, Bertoni C
Degenerative Neurological and Neuromuscular Disease 2016, 6:37-48
Published Date: 13 May 2016
Novel targets for Huntington’s disease: future prospects
Mason SL, Barker RA
Degenerative Neurological and Neuromuscular Disease 2016, 6:25-36
Published Date: 4 May 2016
Orthostatic tremor: current challenges and future prospects
Adebayo PB
Degenerative Neurological and Neuromuscular Disease 2016, 6:17-24
Published Date: 6 April 2016
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Kesayan T, Shaw JD, Jones TM, Staffetti JS, Zesiewicz TA
Degenerative Neurological and Neuromuscular Disease 2016, 6:13-15
Published Date: 3 February 2016
Human immune globulin infusion in the management of multifocal motor neuropathy
Jovanovich E, Karam C
Degenerative Neurological and Neuromuscular Disease 2016, 6:1-12
Published Date: 22 December 2015
MeCP2 in the regulation of neural activity: Rett syndrome pathophysiological perspectives
Cuddapah VA, Nwaobi SE, Percy AK, Olsen ML
Degenerative Neurological and Neuromuscular Disease 2015, 5:103-116
Published Date: 14 October 2015
The role of cell transplantation in modifying the course of limb girdle muscular dystrophy: a longitudinal 5-year study
Sharma A, Sane H, Gokulchandran N, Gandhi S, Bhovad P, Khopkar D, Paranjape A, Bhagwanani K, Badhe P
Degenerative Neurological and Neuromuscular Disease 2015, 5:93-102
Published Date: 14 September 2015
Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study [Corrigendum]
Bisht B, Darling WG, Shivapour ET, Lutgendorf SK, Snetselaar LG, Chenard CA, Wahls TL
Degenerative Neurological and Neuromuscular Disease 2015, 5:91-92
Published Date: 10 September 2015
Clinical and experimental studies of multiple sclerosis in Russia: experience of the leading national research centers
Zavalishin IA, Belogurov AA Jr, Lomakin YA, Ponomarenko NA, Morozova SN, Suslina ZA, Piradov MA, Illarioshkin SN, Gabibov AG
Degenerative Neurological and Neuromuscular Disease 2015, 5:83-90
Published Date: 6 August 2015
Current and emerging treatment options for spinal muscular atrophy
Farooq F, MacKenzie AE
Degenerative Neurological and Neuromuscular Disease 2015, 5:75-81
Published Date: 17 July 2015
Detection of neuropathy using a sudomotor test in type 2 diabetes [Corrigendum]
Gandhi PG, Rao GHR
Degenerative Neurological and Neuromuscular Disease 2015, 5:73-74
Published Date: 16 July 2015
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
Kesayan T, Shaw JD, Jones TM, Staffetti JS, Zesiewicz TA
Degenerative Neurological and Neuromuscular Disease 2015, 5:63-72
Published Date: 3 July 2015
Advances in the management of relapsing–remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
Nielsen AS
Degenerative Neurological and Neuromuscular Disease 2015, 5:51-61
Published Date: 21 May 2015
Clinical diagnosis and management in early Huntington's disease: a review
Schiefer J, Werner CJ, Reetz K
Degenerative Neurological and Neuromuscular Disease 2015, 5:37-50
Published Date: 25 March 2015
Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study
Bisht B, Darling WG, Shivapour ET, Lutgendorf SK, Snetselaar LG, Chenard CA, Wahls TL
Degenerative Neurological and Neuromuscular Disease 2015, 5:19-35
Published Date: 27 February 2015
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
Kotze MJ, Lückhoff HK, Brand T, Pretorius J, van Rensburg SJ
Degenerative Neurological and Neuromuscular Disease 2015, 5:9-18
Published Date: 12 January 2015
Detection of neuropathy using a sudomotor test in type 2 diabetes
Gandhi PG, Rao GHR
Degenerative Neurological and Neuromuscular Disease 2015, 5:1-7
Published Date: 9 January 2015
Optical coherence tomography for retinal imaging in multiple sclerosis
Zimmermann H, Oberwahrenbrock T, Brandt AU, Paul F, Dörr J
Degenerative Neurological and Neuromuscular Disease 2014, 4:153-162
Published Date: 9 December 2014
Use of transcranial magnetic stimulation in the treatment of selected movement disorders
Brown KE, Neva JL, Ledwell NM, Boyd LA
Degenerative Neurological and Neuromuscular Disease 2014, 4:133-151
Published Date: 4 December 2014
Epigenetic mechanisms in Alzheimer’s disease [Corrigendum]
Balazs R
Degenerative Neurological and Neuromuscular Disease 2014, 4:131-132
Published Date: 15 September 2014
Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations
Schindowski C, Zimmermann J, Schindowski K
Degenerative Neurological and Neuromuscular Disease 2014, 4:121-130
Published Date: 5 September 2014
Optimal management of multiple sclerosis during pregnancy: current perspectives
Borisow N, Paul F, Dörr J
Degenerative Neurological and Neuromuscular Disease 2014, 4:111-120
Published Date: 5 August 2014
Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review
Rojas JI, Patrucco L, Cristiano E
Degenerative Neurological and Neuromuscular Disease 2014, 4:103-109
Published Date: 20 June 2014
Epigenetic mechanisms in Alzheimer's disease
Balazs R
Degenerative Neurological and Neuromuscular Disease 2014, 4:85-102
Published Date: 24 May 2014
Identifying responders and nonresponders to interferon therapy in multiple sclerosis
Prosperini L, Capobianco M, Giannì C
Degenerative Neurological and Neuromuscular Disease 2014, 4:75-84
Published Date: 1 April 2014
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
Ethans KD, Casey AR, Bard RJ, Namaka MP
Degenerative Neurological and Neuromuscular Disease 2014, 4:65-73
Published Date: 18 March 2014
Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms
Levin MC, Douglas JN, Meyers L, Lee S, Shin Y, Gardner LA
Degenerative Neurological and Neuromuscular Disease 2014, 4:49-63
Published Date: 12 March 2014
Axonal transport and neurodegenerative disease: vesicle-motor complex formation and their regulation
Anderson EN, White II JA, Gunawardena S
Degenerative Neurological and Neuromuscular Disease 2014, 4:29-47
Published Date: 10 March 2014
Poststroke cognitive impairment and dementia: prevalence, diagnosis, and treatment
Melkas S, Jokinen H, Hietanen M, Erkinjuntti T
Degenerative Neurological and Neuromuscular Disease 2014, 4:21-27
Published Date: 5 February 2014
Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease
Evin G, Barakat A
Degenerative Neurological and Neuromuscular Disease 2014, 4:1-19
Published Date: 22 January 2014
An update on the management of young-onset Parkinson's disease
Klepac N, Habek M, Adamec I, Barušić AK, Bach I, Margetić E, Lušić I
Degenerative Neurological and Neuromuscular Disease 2013, 3:53-62
Published Date: 7 October 2013
Music and dementia
Nair BR, Browne W, Marley J, Heim C
Degenerative Neurological and Neuromuscular Disease 2013, 3:47-51
Published Date: 5 September 2013
Knowledge among physical education professionals about poliomyelitis and post-poliomyelitis syndrome: a cross-sectional study in Brazil
de Lira CA, Almeida Alves TM, Peixinho-Pena LF, Sousa BS, Santana MG, Benite-Ribeiro SA, Andrade MS, Vancini RL
Degenerative Neurological and Neuromuscular Disease 2013, 3:41-46
Published Date: 9 August 2013
Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes
Roussakis AA, Piccini P, Politis M
Degenerative Neurological and Neuromuscular Disease 2013, 3:33-39
Published Date: 28 June 2013
The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration
King RR, Reiss JP
Degenerative Neurological and Neuromuscular Disease 2013, 3:23-31
Published Date: 28 May 2013
Behavioral assessment of visual deficits in the taiep mutant
Bloom CM, Post RJ, Anch AM, Davenport DG
Degenerative Neurological and Neuromuscular Disease 2013, 3:15-21
Published Date: 10 May 2013
The relationship between the apolipoprotein E e4 allele and hippocampal magnetic resonance imaging volume in community-dwelling individuals with mild Alzheimer's disease
Walsh B, Slater S, Nair B, Attia J
Degenerative Neurological and Neuromuscular Disease 2013, 3:11-14
Published Date: 3 March 2013
The pharmacologic management of depression in Parkinson's disease
Schreiber MA, Thompson AW
Degenerative Neurological and Neuromuscular Disease 2013, 3:1-9
Published Date: 18 January 2013
Pathogenic mechanisms of neurodegeneration based on the phenotypic expression of progressive forms of immune-mediated neurologic disease
Levin MC, Lee S, Gardner LA, Shin Y, Douglas JN, Groover CJ
Degenerative Neurological and Neuromuscular Disease 2012, 2:175-187
Published Date: 5 December 2012
Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy
Buxbaum JN
Degenerative Neurological and Neuromuscular Disease 2012, 2:165-173
Published Date: 23 October 2012
Recent advances in Duchenne muscular dystrophy
Perkins KJ, Davies KE
Degenerative Neurological and Neuromuscular Disease 2012, 2:141-164
Published Date: 12 October 2012
Optimal management for people with severe spasticity
Shilt JS, Seibert PS, Kadyan V
Degenerative Neurological and Neuromuscular Disease 2012, 2:133-140
Published Date: 4 October 2012
BG-12 and its potential for the prevention of relapse in multiple sclerosis
Giannetti P, Niccolini F, Nicholas R
Degenerative Neurological and Neuromuscular Disease 2012, 2:119-132
Published Date: 1 October 2012
Deep brain stimulation for the treatment of Parkinson’s disease: efficacy and safety
Pouratian N, Thakkar S, Kim W, Bronstein JM
Degenerative Neurological and Neuromuscular Disease 2012, 2:107-117
Published Date: 4 September 2012
New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience
Suhr OB, Gustavsson S, Heldestad V, Hörnsten R, Lindqvist P, Nordh E, Wiklund U
Degenerative Neurological and Neuromuscular Disease 2012, 2:93-106
Published Date: 29 August 2012
Stem cells and regenerative therapies for Parkinson’s disease
Farrell K, Barker RA
Degenerative Neurological and Neuromuscular Disease 2012, 2:79-92
Published Date: 19 July 2012
Cell adhesion molecules in Alzheimer's disease
Wennström M, Nielsen HM
Degenerative Neurological and Neuromuscular Disease 2012, 2:65-77
Published Date: 5 July 2012
Walking impairment in patients with multiple sclerosis – a new therapeutic approach and clinical potential of dalfampridine extended release tablets
Henney III HR, Blight AR
Degenerative Neurological and Neuromuscular Disease 2012, 2:53-64
Published Date: 25 June 2012
Inclusion body myositis: therapeutic approaches
Aggarwal R, Oddis CV
Degenerative Neurological and Neuromuscular Disease 2012, 2:43-52
Published Date: 10 May 2012
Update on pediatric dystonias: etiology, epidemiology, and management
Fernández-Alvarez E, Nardocci N
Degenerative Neurological and Neuromuscular Disease 2012, 2:29-41
Published Date: 12 April 2012
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
Nwankwo E, Allington DR, Rivey MP
Degenerative Neurological and Neuromuscular Disease 2012, 2:15-28
Published Date: 13 March 2012
Amyotrophic lateral sclerosis: update and new developments
Pratt AJ, Getzoff ED, Perry JJ
Degenerative Neurological and Neuromuscular Disease 2012, 2:1-14
Published Date: 24 February 2012
Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab
Niino M
Degenerative Neurological and Neuromuscular Disease 2011, 1:33-42
Published Date: 3 October 2011
Profile of oral laquinimod and its potential in the treatment of multiple sclerosis
West MS, Miravalle A
Degenerative Neurological and Neuromuscular Disease 2011, 1:25-32
Published Date: 22 July 2011
Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids
Ashton JC
Degenerative Neurological and Neuromuscular Disease 2011, 1:15-23
Published Date: 17 June 2011
Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease
Singh I, Grossberg GT
Degenerative Neurological and Neuromuscular Disease 2011, 1:9-13
Published Date: 10 June 2011
Evaluation of glycopyrrolate in the treatment of chronic drooling
Reddihough DS, Reid SM, Plover C
Degenerative Neurological and Neuromuscular Disease 2011, 1:3-7
Published Date: 18 May 2011
Editorial
Glenn Lopate
Degenerative Neurological and Neuromuscular Disease 2011, 1:1-2
Published Date: 18 March 2011